Human Immunology News Volume 3.35 | Sep 8 2015

    0
    94
    Human Immunology News 3.35 September 8, 2015

    Human Immunology News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Like Us on Facebook   HIN on Twitter

     
    TOP STORY
    Researchers Report Long-Term Remissions in First Group of Patients to Receive Personalized Cellular Therapy for Chronic Lymphocytic Leukemia
    Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia responded to the therapy, with some complete remissions continuing past four and a half years. [Press release from the University of Pennsylvania discussing online publication in Science Translational Medicine] Press Release | Abstract
    Isolate particle-free human CD4+CD127lowCD25+ regulatory T cells (Tregs) in less than one hour. Request a sample today.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Low-Dose Interleukin-2 Selectively Corrects Regulatory T Cell Defects in Patients with Systemic Lupus Erythematosus
    Peripheral blood mononuclear cells (PBMC) from 61 patients with systemic lupus erythematosus and 52 healthy donors and in vitro IL-2 stimulated PBMC were characterized by multicolor flow cytometry. [Ann Rheum Dis] Abstract

    Double-Negative αβ T Cells Are Early Responders to AKI and Are Found in Human Kidney
    Researchers phenotypically and functionally characterized murine kidney CD4−CD8− (double-negative; DN) T cells in the steady state and in response to ischemia-reperfusion injury. DN T cells also made up a large fraction of the T cell compartment in human kidneys. [J Am Soc Nephrol] Abstract

    IL-11 Induces Differentiation of Myeloid-Derived Suppressor Cells through Activation of STAT3 Signaling Pathway
    Scientists found that CD11b+CD14+ monocytic myeloid-derived suppressor cells were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors in the presence of interleukin (IL)-11. IL-11-conditioned PBMCs induced higher expression of immunosuppressive molecules such as arginase-1. [Sci Rep] Full Article

    Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors
    T cells from primary tumor and blood of sixteen patients with pancreatic cancer were characterized by deep sequencing. By analyzing the complementary determining region 3 gene sequence, investigators found no significant differences in the T cell receptor repertoires between patients and healthy controls. [Sci Rep] Full Article

    Low Marginal Zone-Like B Lymphocytes and Natural Antibodies Characterize Skewed B-Lymphocyte Subpopulations in del22q11 diGeorge Patients
    The authors characterized the B-cell compartment in diGeorge syndrome patients. They observed a significantly increased number of naive B-cells and decreased number of switched memory B-cells in diGeorge patients. [Clin Immunol] Abstract

    Effects of Aging on Human Leukocytes (Part II): Immunophenotyping of Adaptive Immune B and T Cell Subsets
    Scientists investigated alterations in the subpopulations of the B and T cells among 24 healthy young and 26 healthy elderly individuals. γδTCR+ T cells were overall decreased, while CD4+CD8− cells among γδTCR+ T cells were increased in the elderly. [Age] Abstract

    Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells
    The authors showed in healthy volunteers that a booster vaccination with tetanus toxoid (TT) expanded peripheral blood TT-specific CD4+ T helper memory (Thmem) cells as expected, but was accompanied by parallel increase of Thmem cells specific for two unrelated and non cross-reactive common recall antigens. In a new cohort of healthy human subjects, they compared blood vaccine-specific and bystander Thmem cells in terms of differentiation stage, function, activation and proliferative status. [PLoS One] Full Article

    Low HIP1R mRNA and Protein Expression Are Associated with Worse Survival in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
    Researchers have previously shown that low HIP1R protein expression was associated with poorer survival in diffuse large B-cell lymphoma patients from Denmark treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). They extended these findings and validated the prognostic and subtyping utility of HIP1R expression at both transcript and protein level. [Exp Mol Pathol] Abstract

    Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

    Request a Sample: 8 minutes to highly purified immune cells with EasySepâ„¢.

     
    REVIEWS
    BTK Signaling in B Cell Differentiation and Autoimmunity
    The authors focus on the role of Bruton’s tyrosine kinase (BTK) during B cell differentiation in vivo, both in the regulation of expansion and in the developmental progression of pre-B cells in the bone marrow and as a crucial signal transducer of signals downstream of the IgM or IgG B cell antigen receptor in mature B cells governing proliferation, survival, and differentiation. [Curr Top Microbiol Immunol] Abstract

    Visit our reviews page to see a complete list of reviews in the human immunology research field.

     
    INDUSTRY NEWS
    Wistar Institute-Spark Therapeutics, Inc. Announce Research Collaboration to Study Human Immune Responses to Liver-Directed Gene Therapy Vectors
    The Wistar Institute and Spark Therapeutics announced a collaboration designed to improve the durability of gene therapy treatments targeting the liver by advancing new ways to manage the immune response to treatment. [The Wistar Institute] Press Release

    OBI Pharma to Unblind Its Phase II/III Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
    OBI Pharma, Inc. announced it plans to unblind its flagship OBI-822/821 Phase II/III clinical trial by March 2016. [OBI Pharma, Inc.] Press Release

    Glenmark’s Novel Monoclonal Antibody GBR 830 to Enter Phase II Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe
    Glenmark Pharmaceuticals S.A announced that GBR 830, a novel monoclonal antibody, has completed clinical Phase I dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. [Glenmark Pharmaceuticals S.A] Press Release

    From our sponsor: Learn how to isolate cells from whole blood in 25 minutes. Watch the video.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW BioChina International 2015 Summit
    October 27-28, 2015
    Shanghai, China

    NEW Keystone Symposia: T Follicular Helper Cells and Germinal Centers
    February 26-March 1, 2016
    Monterey, United States

    Visit our events page to see a complete list of events in the human immunology community.

     
    JOB OPPORTUNITIES
    NEW Principal Scientist – Translational Medicine (Celgene Corporation)

    Tenure Track or Early Career/Tenured Investigator – Immunology (National Institutes of Health – National Heart, Lung, and Blood Institute)

    Postdoctoral Position – Neuroimmunology (Brain and Spine Institute (ICM))

    Senior Research Technician (Qu Biologics Inc.)

    Postdoctoral Research Fellow – Development and Pathogenesis of Pancreatic Cancer (University College London)

    Faculty Positions – Stem Cell/Immunology/Medical Virology (Hallym University Medical Center)

    Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

    Postdoctoral Positions – Cancer Research (Rutgers University)

    Research Associate – Cell Biology (Editas Medicine)

    Senior Research Associate (Editas Medicine)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Human Immunology News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Human Immunology News: Archives | Events | Contact Us